Addex Therapeutics (ADXN) Common Equity (2018 - 2025)
Addex Therapeutics' Common Equity history spans 8 years, with the latest figure at $6.0 million for Q4 2025.
- On a quarterly basis, Common Equity fell 46.01% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 46.01% decrease, with the full-year FY2025 number at $5.7 million, down 47.96% from a year prior.
- Common Equity came in at $6.0 million for Q4 2025, down from $7.4 million in the prior quarter.
- The five-year high for Common Equity was $22.9 million in Q1 2021, with the low at -$1.6 million in Q1 2024.
- Historically, Common Equity has averaged $9.6 million across 5 years, with a median of $8.5 million in 2022.
- Peak annual rise in Common Equity hit 755.45% in 2024, while the deepest fall reached 135.74% in 2024.
- Year by year, Common Equity stood at $18.4 million in 2021, then plummeted by 72.23% to $5.1 million in 2022, then plummeted by 74.68% to $1.3 million in 2023, then surged by 755.45% to $11.0 million in 2024, then tumbled by 46.01% to $6.0 million in 2025.
- Business Quant data shows Common Equity for ADXN at $6.0 million in Q4 2025, $7.4 million in Q3 2025, and $8.7 million in Q2 2025.